TREMFYA Market

“TREMFYA Market Size, Forecast, and Market Insight − 2032” report offers an in-depth analysis of both market and emerging insights regarding TREMFYA for the treatment of Crohn's disease (CD), ulcerative colitis (UC), psoriatic arthritis (PsA), in the seven major markets. A detailed picture of the TREMFYA for ulcerative colitis (UC), psoriatic arthritis (PsA), and ulcerative colitis (UC) in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2019 –2032 is provided in this report along with a detailed description of the TREMFYA. The TREMFYA sales forecasting report provides insights about TREMFYA mechanism of action, dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the TREMFYA market forecast analysis in the 7MM, SWOT, analysts’ views, comprehensive overview of market competitors, and brief about other emerging therapies in Crohn's disease (CD), ulcerative colitis (UC), and psoriatic arthritis (PsA).

TREMFYA Drug Summary

TREMFYA (guselkumab) is a human monoclonal antibody against the p19 subunit of interleukin (IL)-23 developed by Janssen. IL-23 is an important driver of the pathogenesis of inflammatory diseases such as Crohn's disease (CD), ulcerative colitis (UC), and psoriatic arthritis (PsA). Guselkumab, an interleukin-23 blocker, is a human immunoglobulin G1 lambda (IgG1λ) monoclonal antibody produced in a mammalian cell line using recombinant DNA technology. It selectively binds to the p19 subunit of interleukin 23 (IL-23) and inhibits its interaction with the IL-23 receptor. IL-23 is a naturally occurring cytokine involved in normal inflammatory and immune responses. Guselkumab inhibits the release of pro-inflammatory cytokines and chemokines.

TREMFYA (guselkumab) is a prescription biologic medication primarily used for the treatment of moderate to severe plaque psoriasis and active psoriatic arthritis in adults. It works by targeting and blocking interleukin-23 (IL-23), a key protein involved in inflammatory processes. TREMFYA is administered via subcutaneous injection and is typically dosed once every eight weeks following two starter doses. TREMFYA manufacturer "Janssen Biotech, Inc.", a pharmaceutical company under the umbrella of Johnson & Johnson. The cost of TREMFYA can vary depending on insurance coverage and location, but the list price is approximately $13,000 per injection, which totals around $78,000 annually for ongoing treatment. Patients are encouraged to consult their healthcare provider and insurance company to understand their out-of-pocket expenses and potential eligibility for savings programs.

Scope of the TREMFYA Market Report

The TREMFYA Market report provides insights into:

• A comprehensive product overview including the TREMFYA description, TREMFYA mechanism of action, dosage and administration, research and development activities in Crohn's disease (CD), ulcerative colitis (UC), and psoriatic arthritis (PsA).
• Elaborated details on TREMFYA regulatory milestones and other development activities have been provided in this report.
• The TREMFYA Market report also highlights the TREMFYA research and development activities in Crohn's disease (CD), ulcerative colitis (UC), psoriatic arthritis (PsA), and ulcerative colitis (UC) across the United States, Europe, and Japan.
• The TREMFYA Market report also covers the patents information with expiry timeline around TREMFYA.
• The TREMFYA Market report contains forecasted TREMFYA sales for Crohn's disease (CD), ulcerative colitis (UC), psoriatic arthritis (PsA), and ulcerative colitis (UC) till 2032.
• Comprehensive coverage of the late-stage emerging therapies for Crohn's disease (CD), ulcerative colitis (UC), and psoriatic arthritis (PsA).
• The TREMFYA Market report also features the SWOT analysis with analyst views for TREMFYA in Crohn's disease (CD), ulcerative colitis (UC), and psoriatic arthritis (PsA).

TREMFYA Methodology

The TREMFYA Market report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight’s team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

TREMFYA Analytical Perspective by DelveInsight

• In-depth TREMFYA Market Assessment

This TREMFYA Market report provides a detailed market assessment of TREMFYA for Crohn's disease (CD), ulcerative colitis (UC), psoriatic arthritis (PsA), and ulcerative colitis (UC) in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides forecasted TREMFYA sales data from 2024 to 2032.

• TREMFYA Clinical Assessment

The TREMFYA Market report provides the clinical trials information of TREMFYA for Crohn's disease (CD), ulcerative colitis (UC), and psoriatic arthritis (PsA) covering trial interventions, trial conditions, trial status, start and completion dates.

TREMFYA Market Report Highlights 

• In the coming years, the market scenario for Crohn's disease (CD), ulcerative colitis (UC), psoriatic arthritis (PsA), and ulcerative colitis (UC) is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the TREMFYA manufacturers to penetrate more into the market.  
• The TREMFYA companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence TREMFYA dominance.
• Other emerging TREMFYA products for Crohn's disease (CD), ulcerative colitis (UC), psoriatic arthritis (PsA), and ulcerative colitis (UC) are expected to give tough market competition to TREMFYA and launch of late-stage emerging therapies in the near future will significantly impact the TREMFYA market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of TREMFYA in Crohn's disease (CD), ulcerative colitis (UC), and psoriatic arthritis (PsA).
• Our in-depth analysis of the forecasted TREMFYA sales data from 2024 to 2032 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the TREMFYA in Crohn's disease (CD), ulcerative colitis (UC), and psoriatic arthritis (PsA).

Key Questions

• What is the product type, route of administration and mechanism of action of TREMFYA?
• What is the TREMFYA clinical trial status of the study related in Crohn's disease (CD), ulcerative colitis (UC), psoriatic arthritis (PsA), and ulcerative colitis (UC) and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the TREMFYA development?
• What are the key designations that have been granted to TREMFYA for Crohn's disease (CD), ulcerative colitis (UC), psoriatic arthritis (PsA), and ulcerative colitis (UC)?
• What is the forecasted market scenario of TREMFYA for Crohn's disease (CD), ulcerative colitis (UC), psoriatic arthritis (PsA), and ulcerative colitis (UC)?
• What are the forecasted sales of TREMFYA in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain) and the United Kingdom, and Japan? 
• What are the other emerging products available and how are these giving competition to TREMFYA for Crohn's disease (CD), ulcerative colitis (UC), psoriatic arthritis (PsA), and ulcerative colitis (UC)?
• Which are the late-stage emerging therapies under development for the treatment of Crohn's disease (CD), ulcerative colitis (UC), psoriatic arthritis (PsA), and ulcerative colitis (UC)